Literature DB >> 11290834

Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene.

P N Duchateau1, C R Pullinger, M H Cho, C Eng, J P Kane.   

Abstract

Previously we identified and cloned the cDNA for a new protein, apolipoprotein L (apoL), present in plasma and mainly associated with large high density lipoprotein particles. Using 5' rapid amplification of cDNA ends, RT-PCR and comparison with three Human Genome Project and three expressed sequence tag sequences, we have characterized the gene for apoL and for three additional, highly homologous proteins that constitute a new family of proteins that display no homology with previously described apolipoproteins. The genes for all four proteins, apoL-I, apoL-II, apoL-III, and apoL-IV, are located at chromosome 22q12.1-13.1 within a 127,000-bp region. The apoL-I gene is in the opposite orientation to the other three. All four genes have TATA-less promoters, which contain putative sterol regulatory elements, suggesting that transcription of these genes may be coordinated with that of the low density lipoprotein receptor and genes in pathways involving the synthesis of triglycerides and cholesterol. The gene family has a consensus eight-exon structure with alternative splice sites that could produce as many as eight distinct gene products. The apoL-II and apoL-III genes have alternative transcriptional start sites as a result of additional 5' exons. apoL-I, apoL-II, and apoL-III are expressed to the highest degree in the lung. Other tissues with high expression are the pancreas, prostate, spleen, liver, and placenta. Four clustered common polymorphisms, three of which altered the protein sequence, were found in apoL-I, all in linkage disequilibrium, and describing two haplotypes: the more common Lys166/Ile244/Lys271 and the rarer Glu166/Met244/Arg271.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290834

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  67 in total

1.  Population-based risk assessment of APOL1 on renal disease.

Authors:  David J Friedman; Julia Kozlitina; Giulio Genovese; Prachi Jog; Martin R Pollak
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

Review 2.  ApoL1 and the Immune Response of Patients with Systemic Lupus Erythematosus.

Authors:  Ashira D Blazer; Robert M Clancy
Journal:  Curr Rheumatol Rep       Date:  2017-03       Impact factor: 4.592

Review 3.  APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Authors:  Pazit Beckerman; Katalin Susztak
Journal:  Trends Mol Med       Date:  2018-06-07       Impact factor: 11.951

4.  APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition Pore.

Authors:  Shrijal S Shah; Herbert Lannon; Leny Dias; Jia-Yue Zhang; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  J Am Soc Nephrol       Date:  2019-09-26       Impact factor: 10.121

5.  The innate immune factor apolipoprotein L1 restricts HIV-1 infection.

Authors:  Harry E Taylor; Atanu K Khatua; Waldemar Popik
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

6.  Immunobiology of African trypanosomes: need of alternative interventions.

Authors:  Toya Nath Baral
Journal:  J Biomed Biotechnol       Date:  2010-02-23

7.  Differential gene expression during terminal erythroid differentiation.

Authors:  S Koury; S Yarlagadda; K Moskalik-Liermo; N Popli; N Kim; C Apolito; A Peterson; X Zhang; P Zu; J Tamburlin; D Bofinger
Journal:  Genomics       Date:  2007-08-31       Impact factor: 5.736

8.  Polymorphisms in the Apolipoprotein L1 gene and their effects on blood lipid and glucose levels in middle age males.

Authors:  Nigel M Page; Estibaliz Olano-Martin; Christopher Lanaway; Rufus Turner; Anne Marie Minihane
Journal:  Genes Nutr       Date:  2006-06       Impact factor: 5.523

Review 9.  Genomic approaches in the search for molecular biomarkers in chronic kidney disease.

Authors:  M Cañadas-Garre; K Anderson; J McGoldrick; A P Maxwell; A J McKnight
Journal:  J Transl Med       Date:  2018-10-25       Impact factor: 5.531

10.  C-terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense.

Authors:  Laurence Lecordier; Benoit Vanhollebeke; Philippe Poelvoorde; Patricia Tebabi; Françoise Paturiaux-Hanocq; Fabienne Andris; Laurence Lins; Etienne Pays
Journal:  PLoS Pathog       Date:  2009-12-04       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.